

Jashin J Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3219919/publications.pdf>

Version: 2024-02-01

329
papers

9,365
citations

53794

45
h-index

53230

85
g-index

342
all docs

342
docs citations

342
times ranked

8381
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1252-1256.	2.2	4
2	Clinical management of psoriasis patients during the COVID-19 pandemic. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1166-1167.	2.2	11
3	Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 626-636.	2.2	18
4	Association between psoriasis and thyroid dysfunction among US adults in the 2009-2014 National Health and Nutrition Examination Survey. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 897-899.	1.2	5
5	An evaluation of shade-seeking and long-sleeved shirt use in Asian Americans. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 927-929.	1.2	3
6	Asian Americans are less likely to wear sunscreen compared with non-Hispanic whites. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 167-169.	1.2	9
7	Association between psoriasis and asthma among United States adults in the 2009-2014 National Health and Nutrition Examination Survey. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 709-712.	1.2	3
8	The risk of COVID-19 infection in patients with atopic dermatitis: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 243-245.	1.2	17
9	Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 797-806.	2.4	36
10	Anti-drug antibodies of IL-23 inhibitors for psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1171-1177.	2.4	10
11	Review of treatments for generalized pustular psoriasis. <i>Journal of Dermatological Treatment</i> , 2021, 32, 492-494.	2.2	19
12	Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. <i>Journal of Dermatological Treatment</i> , 2021, 32, 693-700.	2.2	7
13	Use of systemic therapies for psoriasis in the COVID-19 era. <i>Journal of Dermatological Treatment</i> , 2021, , 1-4.	2.2	10
14	Improvement in body surface area is associated with better quality of life among patients with psoriasis in the Corrona Psoriasis Registry. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1715-1717.	1.2	1
15	Joint AAD/NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 432-470.	1.2	135
16	Interleukin 23 Inhibitors. , 2021, , 321-329.e2.		0
17	Reply to Letter to the Editor Regarding: "Applying to dermatology residency during the COVID-19 pandemic". <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e31-e32.	1.2	0
18	Two-Year US Pharmacovigilance Report on Brodalumab. <i>Dermatology and Therapy</i> , 2021, 11, 173-180.	3.0	15

#	ARTICLE	IF	CITATIONS
19	Prevalence of psoriasis among adults in the US 2009-2010 and 2013-2014 National Health and Nutrition Examination Surveys. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 767-769.	1.2	17
20	A response to "Male balding is a major risk factor for severe COVID-19". <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e87-e88.	1.2	2
21	Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. <i>Journal of Dermatological Treatment</i> , 2021, 32, 484-491.	2.2	4
22	A systematic review of treatment strategies for erythrodermic psoriasis. <i>Journal of Dermatological Treatment</i> , 2021, 32, 49-55.	2.2	17
23	Abrocitinib for atopic dermatitis. <i>Lancet</i> , The, 2021, 397, 195-196.	13.7	3
24	Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris. <i>Journal of Dermatological Treatment</i> , 2021, , 1-3.	2.2	3
25	The influence of race/ethnicity and skin reaction to sun on sunscreen use. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	2
26	Association between atopic dermatitis and osteoarthritis among US adults in the 1999-2006 NHANES. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e375-e377.	2.4	2
27	Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 157-167.	1.4	2
28	Characterization of nonresponders to interleukin-17 inhibitors in moderate to severe psoriasis patients enrolled in the Corrona Psoriasis Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e531-e533.	2.4	1
29	Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 425-442.	6.7	55
30	Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: A critical appraisal and comprehensive review. <i>Dermatologic Therapy</i> , 2021, 34, e14974.	1.7	2
31	Preliminary outcomes of 2020-2021 dermatology residency application cycle and adverse effects of COVID-19. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e263-e264.	1.2	3
32	Association between psoriasis and rheumatoid arthritis in a nationally representative population in the United States. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	1
33	Characteristics of hospitalizations and emergency department visits due to generalized pustular psoriasis in the United States. <i>Current Medical Research and Opinion</i> , 2021, 37, 1697-1703.	1.9	14
34	The Use of Real-World Data to Evaluate the Association Between Atopic Dermatitis and Cardiovascular Disease: A Retrospective Claims Analysis. <i>Dermatology and Therapy</i> , 2021, 11, 1707-1715.	3.0	6
35	Reply to "Correspondence to "Association between psoriasis and asthma among United States adults in the 2009-2014 National Health and Nutrition Examination Survey". <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	0
36	Bimekizumab versus Adalimumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 1149-1150.	27.0	3

#	ARTICLE	IF	CITATIONS
37	Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial. <i>Dermatology and Therapy</i> , 2021, 11, 327-330.	3.0	4
38	Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE). <i>Journal of Dermatological Treatment</i> , 2021, 32, 883-893.	2.2	11
39	Biologics update: IL-17 inhibitors. <i>Dermatological Reviews</i> , 2021, 2, 269.	0.5	1
40	Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2021, 11, 2147-2157.	3.0	4
41	Topical treatment of psoriasis: questionnaire results on topical therapy as long-term continuous treatment and use on specific body sites. <i>Journal of Dermatological Treatment</i> , 2021, 32, 916-921.	2.2	6
42	Atopic Dermatitis Topical Therapies: Study of YouTube Videos as a Source of Patient Information. , 2021, 108, 139-141.		1
43	Free open access data sources for dermatology researchers. <i>Dermatology Online Journal</i> , 2021, 27, .	0.5	0
44	Comparison of Guidelines for the Use of Interleukin-17 Inhibitors for Psoriasis in the United States, Britain, and Europe: A Critical Appraisal and Comprehensive Review. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2021, 14, 55-59.	0.1	0
45	Phototherapy trends in dermatology 2015-2018. <i>Journal of Dermatological Treatment</i> , 2021, , 1-2.	2.2	1
46	A cross-sectional study of YouTube videos as a source of patient information about phototherapy and excimer laser for psoriasis. <i>Journal of Dermatological Treatment</i> , 2020, 31, 707-710.	2.2	12
47	Psoriasis-associated itch: etiology, assessment, impact, and management. <i>Journal of Dermatological Treatment</i> , 2020, 31, 18-26.	2.2	8
48	Treatments for inverse psoriasis: a systematic review. <i>Journal of Dermatological Treatment</i> , 2020, 31, 786-793.	2.2	13
49	Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review. <i>Journal of Dermatological Treatment</i> , 2020, 31, 342-343.	2.2	13
50	A cross-sectional study of YouTube videos as a source of patient information about topical psoriasis therapies. <i>Journal of Dermatological Treatment</i> , 2020, 31, 366-369.	2.2	14
51	Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions. <i>Journal of Dermatological Treatment</i> , 2020, 31, 359-365.	2.2	16
52	Treatment patterns and healthcare costs among biologic-naïve patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis. <i>Current Medical Research and Opinion</i> , 2020, 36, 169-176.	1.9	9
53	Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials. <i>British Journal of Dermatology</i> , 2020, 182, 880-888.	1.5	20
54	Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease—A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 351-360.	1.3	58

#	ARTICLE	IF	CITATIONS
55	Joint American Academy of Dermatologyâ€™National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 161-201.	1.2	129
56	Applying to dermatology residency during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1214-1215.	1.2	7
57	Real-world switch patterns and healthcare costs in biologic-naïve psoriasis patients initiating apremilast or biologics. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 767-779.	1.4	8
58	Ruxolitinib cream for the treatment of vitiligo. <i>Lancet, The</i> , 2020, 396, 1735-1736.	13.7	3
59	Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e433-e434.	1.2	1
60	The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence. <i>Advances in Therapy</i> , 2020, 37, 4491-4518.	2.9	25
61	Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review. <i>Journal of Dermatological Treatment</i> , 2020, , 1-6.	2.2	1
62	Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e251-e252.	1.2	16
63	Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 459-466.	2.4	4
64	Joint American Academy of Dermatologyâ€™National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1445-1486.	1.2	184
65	Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 483-491.	6.7	16
66	Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. <i>Journal of Medical Economics</i> , 2020, 23, 641-649.	2.1	6
67	Risk of tuberculosis reactivation during interleukinâ€17 inhibitor therapy for psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1449-1456.	2.4	42
68	Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 649.	4.1	120
69	Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence. <i>Dermatology and Therapy</i> , 2020, 10, 351-364.	3.0	18
70	Efficacious psoriasis treatment improves patients' work productivity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e593-e596.	2.4	1
71	Dupilumab for atopic dermatitis: what are patients learning on YouTube?. <i>Journal of Dermatological Treatment</i> , 2020, , 1-2.	2.2	2
72	Psoriasis and Co-morbidity. <i>Acta Dermato-Venereologica</i> , 2020, 100, 81-87.	1.3	43

#	ARTICLE	IF	CITATIONS
73	One-Year Pharmacovigilance Update of Brodalumab. <i>Journal of Drugs in Dermatology</i> , 2020, 19, 807-808.	0.8	6
74	The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric Comorbidities. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2020, 13, 44-48.	0.1	16
75	Review of European registries for psoriasis. <i>Journal of Dermatological Treatment</i> , 2019, 30, 227-236.	2.2	10
76	Treatment of psoriasis with crisaborole. <i>Journal of Dermatological Treatment</i> , 2019, 30, 156-157.	2.2	18
77	Minimal clinically important difference (<scp>MCID</scp>) for work productivity and activity impairment (<scp>WPAI</scp>) questionnaire in psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 318-324.	2.4	26
78	How to choose between IL-17 inhibitors and IL-23 inhibitors for psoriasis. <i>Journal of Dermatological Treatment</i> , 2019, 30, 374-375.	2.2	0
79	Head-to-head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 42-55.	2.4	7
80	Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis. <i>Journal of Dermatological Treatment</i> , 2019, 30, 110-116.	2.2	29
81	Drug survival of secukinumab for psoriasis in a real-world setting. <i>Journal of Dermatological Treatment</i> , 2019, 30, 150-151.	2.2	14
82	Biosimilars in Dermatology: Analytical, Regulatory, and Clinical Considerations: A Treatise From the Medical Board of the National Psoriasis Foundation. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 125-132.	0.7	1
83	Joint American Academy of Dermatologyâ€“National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 775-804.	1.2	105
84	31-Year-Old Female with Psoriasis on Adalimumab with Loss of Effect. , 2019, , 95-102.		0
85	46-Year-Old with Psoriasis and Chronic Hepatitis C. , 2019, , 139-145.		0
86	Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2019, 9, 407-420.	3.0	17
87	Risk of atypical mycobacterial infections in psoriasis patients during IL-17 inhibitor therapy. <i>Journal of Dermatological Treatment</i> , 2019, 32, 1-2.	2.2	0
88	Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231986565.	2.5	11
89	Chronologic order of appearance of immune-mediated inflammatory diseases relative to diagnosis of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1283-1291.	1.2	15
90	Institute for clinical and economic review (ICER) psoriasis update 2018: what it means for dermatologists treating moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2019, 30, 772-774.	2.2	1

#	ARTICLE	IF	CITATIONS
91	Real-world drug survival of ixekizumab for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 270-272.	1.2	7
92	Evaluating Costs of Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 133-142.	0.7	2
93	Safety of long-term interleukin-23 inhibition in patients with psoriasis. <i>British Journal of Dermatology</i> , 2019, 180, 977-978.	1.5	0
94	Burden and Disease Characteristics of Patients with Psoriatic Arthritis: A Population-based Cross-sectional Study. <i>Journal of Rheumatology</i> , 2019, 46, 716-720.	2.0	11
95	Biosimilars for Psoriasis—Experience from Europe. <i>Current Dermatology Reports</i> , 2019, 8, 26-34.	2.1	6
96	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1029-1072.	1.2	542
97	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1073-1113.	1.2	281
98	Anti-TNF and Physiologic Measures of Metabolic Disease in Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2019, 25, e54-e56.	0.9	0
99	Risk of first-time and recurrent depression in patients with psoriasis: a population-based cohort study. <i>British Journal of Dermatology</i> , 2019, 180, 116-121.	1.5	32
100	Clinical Goals and Barriers to Effective Psoriasis Care. <i>Dermatology and Therapy</i> , 2019, 9, 5-18.	3.0	63
101	The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment. <i>Journal of Dermatological Treatment</i> , 2019, 30, 446-453.	2.2	9
102	YouTube videos on oral systemic therapies for psoriasis: a cross-sectional analysis. <i>Journal of Dermatological Treatment</i> , 2019, 30, 549-549.	2.2	2
103	Real-world treatment patterns and healthcare costs among biologic-naïve patients initiating apremilast or biologics for the treatment of psoriasis. <i>Journal of Medical Economics</i> , 2019, 22, 365-371.	2.1	18
104	Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2019, 30, 454-460.	2.2	15
105	A cross-sectional study of YouTube videos about psoriasis biologics. <i>International Journal of Dermatology</i> , 2019, 58, e61-e62.	1.0	9
106	Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 251-265.e19.	1.2	362
107	Psoriasis-associated cutaneous pain: etiology, assessment, impact, and management. <i>Journal of Dermatological Treatment</i> , 2019, 30, 435-440.	2.2	27
108	The Non-compliant Psoriasis Patient. , 2019, , 71-78.		0

#	ARTICLE	IF	CITATIONS
109	36-Year-Old Severely Obese Male with Worsening Psoriasis. , 2019, , 79-86.		0
110	A 53-Year-Old Female with Psoriasis and Breast Cancer. , 2019, , 103-108.		0
111	79-Year-Old Male with Psoriasis and a History of Melanoma In Situ. , 2019, , 109-115.		0
112	36-Year-Old Female with Bright Red Plaques on the Labia Majora. , 2019, , 45-51.		0
113	47-Year-Old Given BCG Vaccine as a Child. , 2019, , 123-129.		0
114	Appearance of lentiginos in psoriasis patient treated with guselkumab. <i>Dermatology Online Journal</i> , 2019, 25, .	0.5	0
115	Apremilast and phototherapy for treatment of psoriasis in a patient with human immunodeficiency virus. <i>Cutis</i> , 2019, 103, E6-E7.	0.3	2
116	Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review. <i>Journal of Dermatological Treatment</i> , 2018, 29, 671-675.	2.2	13
117	Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. <i>British Journal of Dermatology</i> , 2018, 178, 1064-1071.	1.5	43
118	Guselkumab for the treatment of moderate-to-severe plaque psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 333-344.	3.1	8
119	The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor inhibitors versus phototherapy: An observational cohort study. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 60-68.	1.2	54
120	Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. <i>Journal of Dermatological Treatment</i> , 2018, 29, 769-774.	2.2	29
121	Drug survival of secukinumab for moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2018, 179, 222-222.	1.5	4
122	Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1320-1326.	2.4	39
123	Treatment changes in patients with psoriasis on etanercept or adalimumab: a retrospective chart review. <i>Journal of Dermatological Treatment</i> , 2018, 29, 664-665.	2.2	1
124	The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans. <i>Journal of Medical Economics</i> , 2018, 21, 537-541.	2.1	3
125	Dosage adjustments in patients with psoriasis on adalimumab a retrospective chart review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e292-e293.	2.4	2
126	Comparison of guidelines for the use of TNF inhibitors for psoriasis in the United States, Canada, Europe and the United Kingdom: a critical appraisal and comprehensive review. <i>Journal of Dermatological Treatment</i> , 2018, 29, 586-592.	2.2	7

#	ARTICLE	IF	CITATIONS
127	Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 383-394.	1.2	69
128	Interpreting Clinical Trial Data. , 2018, , 27-36.		2
129	Drug survival of apremilast in patients treated for psoriasis in a real-world setting. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 760-761.	1.2	21
130	Atopic dermatitis 2017: where we were 10â€“15 years ago in psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 100-101.	2.2	2
131	Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 214-220.	5.7	129
132	Review of IL-17 inhibitors for psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 347-352.	2.2	21
133	Epidemiology of mental health comorbidity in psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 487-495.	2.2	59
134	Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 1-13.	6.7	56
135	Drug survival of biologic treatments in psoriasis: a systematic review. <i>Journal of Dermatological Treatment</i> , 2018, 29, 460-466.	2.2	66
136	Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 81-89.e5.	1.2	121
137	Psoriasis in solid organ transplant patients: best practice recommendations from The Medical Board of the National Psoriasis Foundation. <i>Journal of Dermatological Treatment</i> , 2018, 29, 329-333.	2.2	13
138	A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 467-474.	2.2	6
139	Review of the mechanism of action of coal tar in psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 230-232.	2.2	27
140	Risk of aortic aneurysm in patients with psoriasis: a retrospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e54-e56.	2.4	4
141	Duration of psoriatic arthritis as a risk factor for myocardial infarction. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky011.	0.7	3
142	Adverse events associated with apremilast use and withdrawal for psoriasis in a realâ€“world setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e393-e394.	2.4	20
143	Localized Scleroderma, Systemic Sclerosis and Cardiovascular Risk: A Danish Nationwide Cohort Study. <i>Acta Dermato-Venereologica</i> , 2018, 98, 361-365.	1.3	14
144	Psoriasiform Hailey-Hailey Disease Presenting as Erythematous Psoriasiform Plaques Throughout the Body: A Case Report. , 2018, 22, 17-016.		2

#	ARTICLE	IF	CITATIONS
145	Building a Citizen Scientist: Advancing Patient-Centered Psoriasis Research by Empowering Patients as Contributors and Analysts. <i>Dermatology and Therapy</i> , 2018, 8, 405-423.	3.0	4
146	Reply to: "Comment on "Drug survival of apremilast for psoriasis in a real-world setting". <i>Journal of the American Academy of Dermatology</i> , 2018, 79, e85.	1.2	1
147	The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1168-1175.	2.4	89
148	Review of U.S. registries for psoriasis. <i>Journal of Dermatological Treatment</i> , 2017, 28, 697-701.	2.2	6
149	Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study. <i>Circulation</i> , 2017, 136, 263-276.	1.6	113
150	Apremilast for a psoriasis patient with HIV and hepatitis C. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e481-e482.	2.4	26
151	A reply to: "Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials". <i>British Journal of Dermatology</i> , 2017, 177, 580-581.	1.5	1
152	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 290-298.	1.2	137
153	Sites of recurrence in patients following clearance of psoriasis with biologic therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e297-e298.	2.4	3
154	Ixekizumab treatment improves fingernail psoriasis in patients with moderate to severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 477-482.	2.4	71
155	Cutaneous lupus erythematosus and the risk of deep venous thrombosis and pulmonary embolism: A Danish nationwide cohort study. <i>Lupus</i> , 2017, 26, 1435-1439.	1.6	29
156	Adalimumab use in patients with psoriasis and hepatitis B: a case series. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e548-e550.	2.4	3
157	Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e544-e547.	2.4	2
158	Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2017, 376, 2092-2093.	27.0	24
159	Topical treatment of psoriasis: questionnaire results on topical therapy accessibility and influence of body surface area on usage. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1188-1195.	2.4	16
160	Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities. <i>JAAD Case Reports</i> , 2017, 3, 495-497.	0.8	21
161	Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry. <i>Dermatology and Therapy</i> , 2017, 7, 365-381.	3.0	33
162	The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 650-656.e3.	1.2	81

#	ARTICLE	IF	CITATIONS
163	Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1627-1632.	2.4	27
164	Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1999-2009.	2.4	150
165	How similar are the treatment responses to biosimilars in patients with psoriasis? A systematic review of statistical margins in comparative clinical trials. Journal of the American Academy of Dermatology, 2017, 77, 569-572.	1.2	5
166	Reply to: Comment on "Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review". Journal of the American Academy of Dermatology, 2017, 77, e169-e170.	1.2	0
167	Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. British Journal of Dermatology, 2017, 177, 1495-1502.	1.5	48
168	The risk of melanoma and hematologic cancers in patients with psoriasis. Journal of the American Academy of Dermatology, 2017, 76, 639-647.e2.	1.2	39
169	Ten-year mortality is increased after hospitalization for atopic dermatitis compared with the general population, but reduced compared with psoriasis. Journal of the American Academy of Dermatology, 2017, 76, 98-105.	1.2	12
170	Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study. Journal of Dermatological Treatment, 2017, 28, 290-298.	2.2	6
171	Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor- α inhibitors versus methotrexate. Journal of the American Academy of Dermatology, 2017, 76, 81-90.	1.2	94
172	Biosimilars for psoriasis: clinical studies to determine similarity. British Journal of Dermatology, 2017, 177, 23-33.	1.5	16
173	National Psoriasis Foundation Priorities for Patient-Centered Research: Proceedings from the 2016 Conference. Journal of Psoriasis and Psoriatic Arthritis, 2017, 2, 73-80.	0.7	7
174	IL-17 Inhibitors in Moderate-to-Severe Plaque Psoriasis. Journal of Psoriasis and Psoriatic Arthritis, 2017, 2, 82-82.	0.7	0
175	Incidence of Pulmonary Arterial Hypertension in Patients with Psoriasis: A Retrospective Cohort Study. , 2017, 21, 16-073.		11
176	Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 370-381.	0.9	16
177	Herpes Zoster Reactivation in a 40-Year-Old with Psoriasis. , 2017, , 127-132.		0
178	69-Year-Old with Psoriasis and a History of Skin Cancer. , 2017, , 117-126.		0
179	Tuberculosis Infection in a 58-Year-Old with Psoriasis. , 2017, , 133-141.		0
180	Persisting Ulcerating Lesions After Cyclosporine Therapy for Erosions Found in Flexural Sites. Skinmed, 2017, 15, 474-475.	0.0	0

#	ARTICLE	IF	CITATIONS
181	Contemporary management of moderate to severe plaque psoriasis. American Journal of Managed Care, 2017, 23, S403-S416.	1.1	6
182	Population Variations in Rheumatoid Arthritis Treatment and Outcomes, Northern California, 1998â€“2009. , 2016, 20, 4-12.		9
183	Trends in Type of Original Psoriasis Publications by Decade, 1960 to 2010. , 2016, 20, 15-060.		3
184	Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care Setting. , 2016, 20, 15-151.		28
185	Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 396-405.	0.9	18
186	Letter regarding Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. Journal of Psoriasis and Psoriatic Arthritis, 2016, 1, 61-61.	0.7	2
187	Brodalumab, An Anti-IL17RA Monoclonal Antibody, for Psoriasis and Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2016, 1, 91-91.	0.7	1
188	Cyclosporine. , 2016, , 63-73.		0
189	Biosimilars. , 2016, , 163-170.		1
190	Patient Satisfaction and Quality of Life in Psoriasis and Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2016, 1, 141-141.	0.7	0
191	Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. British Journal of Dermatology, 2016, 174, 282-286.	1.5	38
192	Identification of key research needs for topical therapy treatment of psoriasis â€“ a consensus paper by the International Psoriasis Council. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1115-1119.	2.4	25
193	From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 2016, 75, 798-805.e7.	1.2	28
194	Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. Journal of the American Academy of Dermatology, 2016, 75, 897-905.	1.2	38
195	Psoriasis. Nature Reviews Disease Primers, 2016, 2, 16082.	30.5	585
196	Peculiar purpuric macules. Journal of the American Academy of Dermatology, 2016, 75, e49-e50.	1.2	0
197	Family history predicts major adverse cardiovascular events (MACE) in young adults with psoriasis. Journal of the American Academy of Dermatology, 2016, 75, 340-346.	1.2	15
198	Nonâ€“tuberculous mycobacterial infections in psoriasis patients treated with biologics. Journal of the European Academy of Dermatology and Venereology, 2016, 30, e99-e101.	2.4	1

#	ARTICLE	IF	CITATIONS
199	Persistence and failure rates of adalimumab monotherapy in biologic-naïve patients with psoriasis: A retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 575-577.	1.2	4
200	Ixekizumab. , 2016, , 153-162.		0
201	Tender Cystic Structure on the Back in an Infant. <i>Skinmed</i> , 2016, 14, 65-6.	0.0	0
202	Persistence and Failure Rates of Monotherapy Etanercept in Biologic-Naïve Psoriasis Patients: A Retrospective Study. <i>Journal of Drugs in Dermatology</i> , 2016, 15, 1029-30.	0.8	2
203	Top-cited psoriasis authors in 4 high-impact dermatology journals: 2000-2012. <i>Dermatology Online Journal</i> , 2016, 22, .	0.5	0
204	Active tuberculosis in a psoriasis patient treated with tumor necrosis factor inhibitors despite an initial negative tuberculin skin test and no known risk factors. <i>Dermatology Online Journal</i> , 2016, 22, .	0.5	2
205	Oral ponesimod for psoriasis compared to other investigational therapies. <i>Dermatology Online Journal</i> , 2016, 22, .	0.5	0
206	The Evolving Role of Primary Care Practitioners in Dermatology. <i>Journal of the Dermatology Nurses' Association</i> , 2015, 7, 325-329.	0.1	6
207	Total cholesterol, lipoprotein, and triglyceride levels in tumor necrosis factor inhibitor-treated patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis. <i>International Journal of Dermatology</i> , 2015, 54, e442-5.	1.0	6
208	An updated survey for the 2007-2013 period of randomized controlled trials for psoriasis: treatment modalities, study designs, comparators, outcome measures and sponsorship. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1945-1950.	2.4	5
209	Trends in the Frequency of Original Research in Acne Vulgaris, Rosacea, Dermatitis, Psoriasis, Skin Cancer, and Skin Infections, 1970-2010. , 2015, 19, 44-47.		4
210	Pemphigus Vulgaris with Tense Bullae. , 2015, 19, 77-8.		2
211	Risk of myocardial infarction in psoriasis patients: a retrospective cohort study. <i>Journal of Dermatological Treatment</i> , 2015, 26, 230-234.	2.2	31
212	Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 410-419.e6.	1.2	55
213	Treatment of Nail Psoriasis. <i>JAMA Dermatology</i> , 2015, 151, 87.	4.1	88
214	Association between tumor necrosis factor inhibitor (TNFi) therapy and changes in C-reactive protein (CRP), blood pressure, and alanine aminotransferase (ALT) among patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 917-919.	1.2	8
215	Antiviral gene expression in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1951-1957.	2.4	32
216	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , 2015, 373, 1318-1328.	27.0	656

#	ARTICLE	IF	CITATIONS
217	Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 329-331.	1.2	9
218	Preventing hepatitis B reactivation associated with immunosuppressive drug treatments for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 881-882.	1.2	6
219	Survey of trends and gaps in dermatologists' cardiovascular screening practices in psoriasis patients: Areas still in need of improvement. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 872-874.e4.	1.2	14
220	Comment on "Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor- α inhibitors". <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e121.	1.2	1
221	Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 955-963.	2.4	81
222	Melanoma in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 78-84.	1.2	31
223	Photodynamic therapy for psoriasis. <i>Journal of Dermatological Treatment</i> , 2015, 26, 202-207.	2.2	46
224	No association between TNF inhibitor and methotrexate therapy versus methotrexate in changes in hemoglobin A1C and fasting glucose among psoriasis, psoriatic arthritis, and rheumatoid arthritis patients. <i>Journal of Drugs in Dermatology</i> , 2015, 14, 159-66.	0.8	15
225	Factors affecting academic leadership in dermatology. <i>Cutis</i> , 2015, 95, 98-102.	0.3	0
226	Factors affecting the pursuit of academic careers among dermatology residents. <i>Cutis</i> , 2015, 95, 231-6.	0.3	5
227	Time to Raise the Bar to Psoriasis Area Severity Index 90 and 100. <i>Journal of Drugs in Dermatology</i> , 2015, 14, 1086-8.	0.8	24
228	The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 846-852.	2.4	58
229	Initiation of <sc>TNF</sc> inhibitor therapy and change in physiologic measures in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1380-1387.	2.4	8
230	Effect of Treating Psoriasis on Cardiovascular Co-Morbidities: Focus on TNF Inhibitors. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 45-50.	6.7	27
231	An update on drug-drug interactions with biologics for the treatment of moderate-to-severe psoriasis. <i>Journal of Dermatological Treatment</i> , 2014, 25, 87-89.	2.2	14
232	The risk of deep fungal infections during biologic therapy for psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1277-1285.	2.4	7
233	Bariatric surgery and psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 774-779.	1.2	21
234	Relationship between Tumor Necrosis Factor- α Inhibitors and Cardiovascular Disease in Psoriasis: A Review. , 2014, 18, 49-54.		15

#	ARTICLE	IF	CITATIONS
235	Most Common Dermatologic Topics Published in Five High-Impact General Medical Journals, 1970-2012: Melanoma, Psoriasis, Herpes Simplex, Herpes Zoster, and Acne. , 2014, 18, 29-31.		2
236	US dermatology residency program rankings. <i>Cutis</i> , 2014, 94, 189-94.	0.3	6
237	A randomized, head-to-head™ pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 899-906.	2.4	34
238	Association of ethnicity, tumor necrosis factor inhibitor therapy, and myocardial infarction risk in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 167-168.	1.2	9
239	Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996–2009. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 842-849.	1.9	94
240	Bullous drug eruption in a patient with psoriasis after a test dose of methotrexate. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, e264-e265.	1.2	3
241	Association of gender, tumor necrosis factor inhibitor therapy, and myocardial infarction risk in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 650-651.	1.2	20
242	Psoriasis Flare from Koebner's Phenomenon after Acupuncture. <i>New England Journal of Medicine</i> , 2013, 368, 1635-1635.	27.0	7
243	Tumor Necrosis Factor Inhibitors and Myocardial Infarction in Psoriasis. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1075.	7.4	3
244	Incidence and Prevalence of Juvenile Idiopathic Arthritis Among Children in a Managed Care Population, 1996–2009. <i>Journal of Rheumatology</i> , 2013, 40, 1218-1225.	2.0	68
245	Tumor Necrosis Factor- α Triad: Psoriasis, Cardiovascular Disease, and Depression. <i>Psoriasis Forum</i> , 2013, 19a, 41-49.	0.1	3
246	Axillary granular parakeratosis. <i>Cutis</i> , 2013, 92, 61, 65-6.	0.3	0
247	Partial reversal of androgenetic alopecia with methotrexate therapy for psoriasis. <i>Cutis</i> , 2013, 92, 127-8.	0.3	2
248	Combination therapy with tumor necrosis factor inhibitors in psoriasis treatment. <i>Cutis</i> , 2013, 92, 140-7.	0.3	8
249	Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 1244.	1.4	255
250	Pruritic erythematous papules on an actinically damaged scalp. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, e79-e80.	1.2	0
251	The association of psoriasis with autoimmune diseases. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 924-930.	1.2	176
252	A Review of the Epidemiology of Cardiovascular Comorbidities in Psoriasis. <i>Current Dermatology Reports</i> , 2012, 1, 14-22.	2.1	0

#	ARTICLE	IF	CITATIONS
253	Association of systemic psoriasis therapies and incidence of myocardial infarction. <i>British Journal of Dermatology</i> , 2012, 166, 232-232.	1.5	7
254	Cutaneous manifestations of category A bioweapons. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 1213.e1-1213.e15.	1.2	15
255	Low prevalence of psoriasis among children and adolescents in a large multiethnic cohort in southern California. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 957-964.	1.2	43
256	Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 870.	1.2	72
257	Wnt Signaling Regulates Hepatic Metabolism. <i>Science Signaling</i> , 2011, 4, ra6.	3.6	167
258	A Clinical Study Comparing the Efficacy of Halobetasol Propionate 0.05% Ointment Once Daily versus Twice Daily in Combination with Ammonium Lactate Lotion in the Treatment of Stable Plaque Psoriasis. <i>Psoriasis Forum</i> , 2011, 17a, 2-8.	0.1	1
259	The Association of Psoriasis and Elevated Blood Lipids in Overweight and Obese Children. <i>Journal of Pediatrics</i> , 2011, 159, 577-583.	1.8	98
260	Medical Students Educate Teens About Skin Cancer: What Have We Learned?. <i>Journal of Cancer Education</i> , 2011, 26, 153-155.	1.3	10
261	Interaction between adalimumab with concurrent pregabalin and duloxetine administration in a psoriasis patient with diabetic peripheral neuropathy. <i>Cutis</i> , 2011, 87, 249-50.	0.3	6
262	Sunitinib-induced hand-foot syndrome: a new, distinct form. <i>Clinical and Experimental Dermatology</i> , 2010, 35, 200-201.	1.3	7
263	Etanercept as prophylactic psoriatic therapy before interferon- α and ribavirin treatment for active hepatitis C infection. <i>Clinical and Experimental Dermatology</i> , 2010, 35, 397-398.	1.3	27
264	Localized Contact Urticaria Caused by Lidocaine/Tetracaine Peel. <i>Archives of Dermatology</i> , 2009, 145, 499-500.	1.4	7
265	Erythematous Papules and Pustules on the Scalp. <i>Pediatric Dermatology</i> , 2009, 26, 195-196.	0.9	0
266	Effects of tumor necrosis factor- α blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. <i>Dermatologic Therapy</i> , 2009, 22, 61-73.	1.7	80
267	Generalized Chrysiasis Improved with Pulsed Dye Laser. <i>Dermatologic Surgery</i> , 2009, 35, 538-542.	0.8	13
268	308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and palmoplantar psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 36-41.	2.4	43
269	Bortezomib-induced histiocytoid Sweet syndrome. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 496-497.	1.2	46
270	Habit tic deformity secondary to guitar playing. <i>Dermatology Online Journal</i> , 2009, 15, 16.	0.5	3

#	ARTICLE	IF	CITATIONS
271	Graduates-of-foreign-dermatology residencies and military dermatology residencies and women in academic dermatology. <i>Dermatology Online Journal</i> , 2009, 15, 2.	0.5	0
272	Kaiser Permanente: a new model for academic dermatology. <i>Dermatology Online Journal</i> , 2009, 15, 13.	0.5	0
273	Calcinosis Cutis of Juvenile Dermatomyositis Treated with Incision and Drainage. <i>Dermatologic Surgery</i> , 2008, 34, 575-577.	0.8	27
274	Letter: Clear Margins after the Use of Imatinib Mesylate prior to Resection of Extensive Dermatofibrosarcoma Protuberans. <i>Dermatologic Surgery</i> , 2008, 34, 1151-1151.	0.8	1
275	Cutaneous horn on the finger. <i>Clinical and Experimental Dermatology</i> , 2008, 33, 529-530.	1.3	1
276	An indurated, enlarged lower lip. <i>Clinical and Experimental Dermatology</i> , 2008, 33, 799-800.	1.3	2
277	Erythematous, eczematous papules appearing in the spring. <i>Clinical and Experimental Dermatology</i> , 2008, 33, 217-218.	1.3	2
278	Interleukin-12, interleukin-23, and psoriasis: ABT-874 in clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 1083.	1.2	3
279	The Nikolskiy Sign. <i>Archives of Dermatology</i> , 2008, 144, 1140.	1.4	6
280	MD/PhDs are more likely than MDs to choose a career in academic dermatology. <i>Dermatology Online Journal</i> , 2008, 14, 27.	0.5	0
281	Confluent and reticulate papillomatosis. <i>Dermatology Online Journal</i> , 2008, 14, 10.	0.5	0
282	Histopathologic Findings of Disseminated Coccidioidomycosis With Hyphae. <i>Archives of Dermatology</i> , 2007, 143, 543.	1.4	3
283	Clinical Improvement of Pityriasis Rubra Pilaris With Combination Etanercept and Acitretin Therapy. <i>Archives of Dermatology</i> , 2007, 143, 1597-9.	1.4	36
284	Patients seen and lessons learned. <i>Clinics in Dermatology</i> , 2007, 25, 144-145.	1.6	2
285	Current strategies to address the ongoing shortage of academic dermatologists. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 1065-1066.	1.2	3
286	Chronically painful right thumb with pustules and onycholysis. <i>Clinical and Experimental Dermatology</i> , 2007, 32, 619-620.	1.3	17
287	Topical kinetin 0.1% lotion for improving the signs and symptoms of rosacea. <i>Clinical and Experimental Dermatology</i> , 2007, 32, 693-695.	1.3	33
288	Ranking the dermatology programs based on measurements of academic achievement. <i>Dermatology Online Journal</i> , 2007, 13, 3.	0.5	72

#	ARTICLE	IF	CITATIONS
289	Morgellons disease: A rapport-enhancing term for delusions of parasitosis. Journal of the American Academy of Dermatology, 2006, 55, 913-914.	1.2	45
290	Estrogen and the skin. Journal of the American Academy of Dermatology, 2006, 55, 1115-1116.	1.2	0
291	Rickettsial infections. , 2006, , 279-296.		2
292	Postherpetic Poliosis. Archives of Dermatology, 2006, 142, 250.	1.4	13
293	Dermatology Residency Program Characteristics That Correlate With Graduates Selecting an Academic Dermatology Career. Archives of Dermatology, 2006, 142, 845-50.	1.4	31
294	Dermographism secondary to trauma from a coral reef. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 1337-1338.	2.4	4
295	West Nile virus rash on the palms and soles of the feet. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 1393-1394.	2.4	3
296	Thalidomide, semen distribution, teratogenicity and cost: reply from authors. British Journal of Dermatology, 2006, 154, 563-564.	1.5	0
297	Cutaneous metastasis to the chest wall from prostate cancer. International Journal of Dermatology, 2006, 45, 946-948.	1.0	24
298	An unusual presentation of two simultaneous primary melanomas. International Journal of Dermatology, 2006, 45, 580-582.	1.0	3
299	A Unique Pattern of Hyperhidrosis and Herpes Zoster. Archives of Dermatology, 2006, 142, 1065.	1.4	7
300	Tropical manifestations of common viral infections. , 2006, , 171-183.		0
301	Issues for travelers. , 2006, , 13-19.		0
302	Basal Cell and Squamous Cell Carcinoma in Persons Younger Than 40 Years. JAMA - Journal of the American Medical Association, 2006, 295, 278.	7.4	0
303	Rickettsial Infections around the World, Part 2: Rickettsialpox, the Typhus Group, and Bioterrorism. Journal of Cutaneous Medicine and Surgery, 2005, 9, 105-115.	1.2	1
304	Thalidomide: dermatological indications, mechanisms of action and side-effects. British Journal of Dermatology, 2005, 153, 254-273.	1.5	182
305	Corrigendum to "A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines" [Journal of Infection 49 (2004) 179-209]. Journal of Infection, 2005, 51, 174.	3.3	0
306	Rickettsial Infections Around the World, Part 1: Pathophysiology and the Spotted Fever Group. Journal of Cutaneous Medicine and Surgery, 2005, 9, 54-62.	1.2	6

#	ARTICLE	IF	CITATIONS
307	Rickettsial Infections Around the World, Part 2: Rickettsialpox, the Typhus Group, and Bioterrorism. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005, 9, 105-115.	1.2	5
308	Rickettsial Infections around the World, Part 1: Pathophysiology and the Spotted Fever Group. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005, 9, 54-62.	1.2	3
309	Advances in Antiviral Therapy. <i>Dermatologic Clinics</i> , 2005, 23, 313-322.	1.7	12
310	Emerging therapies for herpes viral infections (types 1 & 8). <i>Expert Opinion on Emerging Drugs</i> , 2004, 9, 237-256.	2.4	8
311	Therapy of common superficial fungal infections. <i>Dermatologic Therapy</i> , 2004, 17, 517-522.	1.7	23
312	Subcutaneous fungal infections. <i>Dermatologic Therapy</i> , 2004, 17, 523-531.	1.7	89
313	Therapy of systemic fungal infections. <i>Dermatologic Therapy</i> , 2004, 17, 532-538.	1.7	10
314	Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. <i>Antiviral Research</i> , 2004, 64, 79-83.	4.1	56
315	A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. <i>Journal of Infection</i> , 2004, 49, 179-209.	3.3	49
316	Reactive Hemophagocytosis Associated with the Initiation of Highly Active Antiretroviral Therapy (HAART) in a Patient with AIDS. <i>Scandinavian Journal of Infectious Diseases</i> , 2004, 36, 516-519.	1.5	27
317	Selected sexually transmitted diseases and their relationship to HIV. <i>Clinics in Dermatology</i> , 2004, 22, 499-508.	1.6	29
318	Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, 495-528.	1.2	22
319	Toxic Epidermal Necrolysis as a Complication of Treatment with Voriconazole. <i>Southern Medical Journal</i> , 2004, 97, 1116-1117.	0.7	13
320	Valacyclovir in the Treatment of Herpes Simplex, Herpes Zoster, and Other Viral Infections. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 372-381.	1.2	9
321	Secondary cutaneous anaplastic large cell lymphoma treated with liposomal doxorubicin (DoxilR) leading to complete remission. <i>International Journal of Dermatology</i> , 2003, 42, 464-465.	1.0	3
322	Verruciform Xanthoma in Association with Milroy Disease and Leaky Capillary Syndrome. <i>Pediatric Dermatology</i> , 2003, 20, 44-47.	0.9	34
323	Valacyclovir in the Treatment of Herpes Simplex, Herpes Zoster, and other Viral Infections. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 372-381.	1.2	7
324	Bullous Phytophotodermatitis Associated With High Natural Concentrations of Furanocoumarins in Limes. <i>American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society</i> , 2002, 13, 10-14.	0.4	51

#	ARTICLE	IF	CITATIONS
325	A Case of Air Bag Dermatitis. Archives of Dermatology, 2002, 138, 1383-1384.	1.4	7
326	A case of elastosis perforans serpiginosa. Cutis, 2002, 69, 423-5.	0.3	5
327	Squamous cell carcinoma in solid-organ transplantation. Dermatology Online Journal, 2002, 8, 4.	0.5	77
328	Cytokine-Induced Metabolic Dysfunction of MIN6 β Cells Is Nitric Oxide Independent. Journal of Surgical Research, 2001, 101, 190-195.	1.6	15
329	Effects of simulated source of tremor on acoustic and airflow voice measures. Journal of Voice, 2000, 14, 47-57.	1.5	8